Trial Profile
A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cefiderocol (Primary) ; Amikacin; Avibactam/ceftazidime; Ceftolozane/tazobactam; Ciprofloxacin; Doripenem; Fosfomycin; Gentamicin; Tigecycline; Tobramycin
- Indications Acinetobacter infections; Enterobacter infections; Escherichia coli infections; Gram-negative infections; Klebsiella infections; Nosocomial pneumonia; Pseudomonal infections; Sepsis; Urinary tract infections
- Focus Registrational; Therapeutic Use
- Acronyms CREDIBLE - CR
- Sponsors Shionogi
- 20 Feb 2022 Results of post-hoc analysis of two studies (APEKS-cUTI (NCT02321800), APEKS-NP (NCT03032380) and CREDIBLE-CR (NCT02714595)) assessing cefiderocol efficacy in patients with baseline bacteraemia published in the Infectious Diseases and Therapy.
- 11 Feb 2022 Results from CREDIBLE-CR And APEKS-NP studies published in the Clinical Infectious Diseases
- 18 Nov 2021 data from (APEKS-NP and CREDIBLE-CR) used to develop PK and PD of cefiderocol during in vitro and in vivo CRRT published in the Clinical Pharmacokinetics